Patent ID: 11857574
Assignee: CRISPR THERAPEUTICS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 12:
13. A population of immune cells comprising genetically engineered T cells, wherein the genetically engineered T cells comprise:
(i) a disrupted Regnase-1 (Reg1) gene genetically edited at a Reg1 target site of SEQ ID NO: 327;
(ii) a disrupted Transforming Growth Factor Beta Receptor II (TGFBRII) gene genetically edited at a TGFBRII target site of SEQ ID NO: 317;
(iii) a disrupted a disrupted T cell receptor alpha chain constant region (TRAC) gene genetically edited at a TRAC target site of SEQ ID NO: 69;
(iv) a disrupted beta-2-microglobulin (β2M) gene genetically edited at a β2M target site of SEQ ID NO: 71,
(v) a disrupted CD70 gene genetically edited at a CD70 target site of SEQ ID NO: 67; and
(vi) a nucleic acid encoding a chimeric antigen receptor (CAR) that binds CD70,
wherein the CAR comprises an extracellular antigen binding domain that binds CD70, which comprises a single chain variable fragment (scFv) that comprises the amino acid sequence of SEQ ID NO: 140 or 142; and
wherein the nucleic acid is inserted in the disrupted TRAC gene.